13th Orange County Symposium for Cardiovascular Disease Prevention
Y

SGLT2 inhibitors and GLP-1 agonists: Why Are They Important and Which Do I Choose?

By 13th Orange County Symposium for Cardiovascular Disease Prevention FEATURING Yehuda Handelsman
By 13th Orange County Symposium for Cardiovascular Disease Prevention FEATURING Yehuda Handelsman
0 views
January 27, 2022
Comments 4
Login to view comments. Click here to Login

Featured Video

18:06
Lilly Obesity

Getting Patients Started with an Obesity Treatment Option for Adults

Feat. E. Lazarus

Featured Video

46:20
Lilly Diabetes

A Journey Through Clinical Efficacy and Safety Data Comparing Two In…

Feat. S. Shadid

Recommended

AUTOPLAY
64:45
Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

Primer on Diabetes Management

Feat. S. Inzucchi
12:12
CVRx | Barostim

Challenges and Opportunities with Contemporary GDMT in NYHA Class II…

Feat. W. Abraham
12:04
Stephen Kopecky

Role of PCSK9 Inhibitors in Diabetes

11:37
ACC 2022 Conference Coverage

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

Feat. P. Heidenreich
28:13
National Lipid Association

New Insights into Triglyceride Therapy and the Role of Omega-3 Fatty…

Feat. R. Mason
11:25
ACC 2023 Conference Coverage

ACC 2023: SGLT2i Use - Dos and Don'ts

Feat. A. Armbruster
61:49
Obafemi Awolowo University

Management of Heart Failure

Feat. O. A. Akinyele
18:43
ASPC 2019 Congress on CVD Prevention

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

Feat. R. DeFronzo
27:14
MUSC Cardiology

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

Feat. R. Mentz
15:06
Robert Busch

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

26:01
Cardiology Fiesta 2017

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Feat. R. DeFronzo
12:26
Juan Frias

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

15:33
Ken Fujioka

Could GLP-1's be a 'Game Changer' For Weight Loss? Ca…

17:44
Rita Jermyn

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

27:24
Cardiometabolic Health Congress (CMHC)

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Feat. L. Sloan
26:49
Diana Isaacs

Tirzepatide Updates

09:52
AHA 2022 Conference Coverage

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

Feat. R. Mentz
26:32
Practical Ways to Achieve Targets in Diabetes Care

Metabolic Surgery vs. Pharmacotherapy for Treatment of Obesity

Feat. S. Nissen
13:07
Michelle Kittleson

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

20:24
Diana Isaacs

Tirzepatide for Type 2 Diabetes